MT1013 is named as an intervention in 2 current clinical trials in our China register. 2 are recruiting patients now. The most common phase is Phase 3. The lead sponsor is Shaanxi Micot Pharmaceutical Technology Co., Ltd. The most-studied condition is Secondary Hyperparathyroidism, Chronic Kidney Disease.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism
NCT07122401 · ClinicalTrials.gov ↗ · Secondary Hyperparathyroidism, Chronic Kidney Disease
|
Phase 3 | Recruiting | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | China |
|
Study of MT1013 Injection for the Treatment of Secondary Hyperparathyroidism (SHPT) Patients With Chronic Kidney Disease Undergoing Maintenance Dialysis
NCT06976177 · ClinicalTrials.gov ↗ · Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis
|
Phase 2 | Recruiting | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Shaanxi Micot Pharmaceutical Technology Co., Ltd. | 2 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 2 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China register name MT1013 as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 2 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Shaanxi Micot Pharmaceutical Technology Co., Ltd. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how MT1013 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how MT1013 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists MT1013 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.